Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Vunakizumab on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Vunakizumab is an injectable antibody for psoriasis and ankylosing spondylitis. It was developed in China by Jiangsu Hengrui Pharmaceuticals and is made by its subsidiary Suzhou Suncadia Biopharmaceuticals. In China it is sold as 安达静® and is injected under the skin.
China's National Medical Products Administration (NMPA) has approved it for adults with:
It is a prescription immunology medicine and should be used only under a dermatologist or rheumatologist.
IL-17A is an immune messenger that drives the fast skin-cell growth and redness of psoriasis, and the inflammation in the spine and tendons in ankylosing spondylitis. Vunakizumab is a humanised monoclonal antibody that binds IL-17A and stops it from reaching its receptor, which calms the inflammation at its source. It stays in the body for a long time (a half-life of about 24 days), and after the starting doses it is given once every four weeks.
Psoriasis: the phase 3 trial, published in the Journal of the American Academy of Dermatology in 2025, included 690 adults with moderate-to-severe plaque psoriasis. After 12 weeks, 76.8% of people on vunakizumab had at least 90% clearer skin (PASI 90), against 0.9% on placebo. 93.6% reached PASI 75 and 36.6% had completely clear skin (PASI 100). The benefit held through week 52.
Ankylosing spondylitis: in a phase 2/3 trial of 548 adults (JAMA Network Open, 2026), 65.6% of people on vunakizumab 120 mg reached the ASAS20 response at week 16, compared with 42.5% on placebo, and 46.3% versus 24.0% reached the stricter ASAS40. Responses lasted to week 32.
Each pre-filled pen or syringe holds 120 mg in 1 mL. The regimens used in the trials and described in the published literature are:
Your specialist will confirm the exact schedule from the current Chinese prescribing information and decide how long to continue.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Blood tests: in the psoriasis trial, the most common changes were in blood chemistry. Over 52 weeks, raised uric acid (hyperuricaemia) was seen in 18.9% of patients, high blood fats in 13.3%, high triglycerides in 9.8% and a rise in the liver enzyme ALT in 11.1%. Your doctor may check uric acid, lipids and liver tests from time to time, especially if you have gout, diabetes or a fatty liver.
Overall: during the first 12 weeks of the psoriasis trial, side effects were about as frequent as with placebo (69.1% vs 71.6%). Severe side effects occurred in 1.5% and only 0.7% stopped treatment because of them. Over 52 weeks, 2.2% stopped because of side effects.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For another psoriasis medicine we can import, see our page on Bimzelx.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. It is stored and shipped as directed on the pack, using temperature-controlled shipping all the way to the hospital or patient. Because the starting doses come close together, we plan the first order to cover the loading phase. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the treating hospital or clinic on a valid specialist's prescription.
Dermatologists and rheumatologists in Delhi can request the injection for a named patient, with dispatch from our New Delhi base.
The first order is timed so the closely spaced starting doses arrive together.
Specialists in Bangalore can send the prescription and treatment history to begin the import.
Patients with long-standing psoriasis can have supplies delivered to their treating hospital.
We share a written quote and delivery timeline before anything is ordered.
Shipments to Kolkata and the eastern states are handled under controlled conditions throughout.
Patients with ankylosing spondylitis in Pune can use the same documented import route.
The treating doctor can share earlier treatment details so the import file is complete from the start.
Patients treated at hospitals in Vellore can have monthly supplies sent directly to the hospital.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the treating hospital.
We coordinate delivery to public and private hospitals across Uttar Pradesh.
Patients across Kerala can receive the injection at their hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
.webp)
